This article is more than 5 years old. Information may no longer be current.
Topical eye drops continue to face hurdles
NEW ORLEANS — According to one speaker, topical eye drops have disadvantages: ocular surface toxicity, burden of cost and issues of patient adherence with triple therapy. Compounded combination therapies are a new way to address those disadvantages perioperatively, Damien Goldberg, MD, said during Cornea Day preceding the American Society of Cataract and Refractive Surgery meeting.
“The biggest challenge we find is that the FDA won’t let us do the simplest thing: put all three in one bottle,” he said.
Preservative-free Droplet (Ocular Sciences) and Less Drops (Imprimis) are two products that aim to meet that need.
Goldberg described a multicenter, randomized, observer-masked, prospective study of Droplet vs. current multiple drop therapy: the Droplet 1.0 OS trial. Patients were eligible if they were undergoing unilateral uncomplicated extracapsular phacoemulsification with posterior chamber IOL implantation. Eighty patients are intended to be enrolled.
Primary endpoint is resolved ocular inflammation after cataract surgery; secondary endpoint is reduction in pain.
“So far we have 12 cases that have completed until day 7,” Goldberg said. Of those, seven cases have received compounded therapy and five cases have received the standard triple therapy drops.
Visual acuity for the compounded group vs. the standard drops groups were equivalent at 20/25. – by Patricia Nale, ELS
Reference:
Goldberg D. Drops or no drops following cataract surgery: Drops vs. intracameral vs. transzonular/intravitreal. Presented at: ASCRS; May 6-10, 2016; New Orleans, Louisiana.
Disclosure: Goldberg reports he is a consultant for Alcon, Allergan, Bausch + Lomb, and Ocular Sciences.